Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO. Resolian now has bioanalysis laboratory operations in the U.S., U.K., Australia, and China. “The strategic addition of Denali will significantly enhance our capabilities and strengthen our position in the global market,” said Resolian CEO Patrick Bennett. “Denali’s founders and core scientists are internationally recognized across pharmaceutical research and development analysis and we are particularly excited to add Denali’s oligo, mRNA, and liposomal expertise to Resolian’s portfolio of services.”
Read the full article: Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma //
Source: https://www.businesswire.com/news/home/20231101490232/en/Resolian-Acquires-China-Based-Bioanalytical-CRO-Denali-Medpharma